Philip Wagenheim Net Worth

The estimated Net Worth of Philip Wagenheim is at least $5.75 Millón dollars as of 24 May 2021. Philip Wagenheim owns over 13,500 units of Immunome stock worth over $5,746,361 and over the last 3 years Philip sold IMNM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Philip Wagenheim IMNM stock SEC Form 4 insiders trading

Philip has made over 1 trades of the Immunome stock since 2021, according to the Form 4 filled with the SEC. Most recently Philip bought 13,500 units of IMNM stock worth $247,725 on 24 May 2021.

The largest trade Philip's ever made was buying 13,500 units of Immunome stock on 24 May 2021 worth over $247,725. On average, Philip trades about 2,250 units every 0 days since 2021. As of 24 May 2021 Philip still owns at least 397,397 units of Immunome stock.

You can see the complete history of Philip Wagenheim stock trades at the bottom of the page.

What's Philip Wagenheim's mailing address?

Philip's mailing address filed with the SEC is C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011.

Insiders trading at Immunome

Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime y Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.

What does Immunome do?

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Complete history of Philip Wagenheim stock trades at Immunome

Immunome executives and stock owners

Immunome executives and other stock owners filed with the SEC include:

• Dr. Purnanand Duddu Sarma,
  Pres, CEO & Director
• Sandra G. Stoneman Esq.,
  Chief Legal Officer, Gen. Counsel & Corp. Sec.
• Dr. Michael J. Morin Ph.D.,
  Chief Scientist
• Dr. Scott K. Dessain M.D., Ph.D.,
  Co-founder & Chairman of the Scientific Advisory Board
• Dr. Dennis H. Giesing,
  Chief Devel. Officer
• Matthew K. Robinson Ph.D.,
  Sr. VP of R&D
• Corleen M. Roche,
  Chief Financial Officer
• Michael Widlitz,
  Director
• Michael Lefenfeld,
  Director
• Dennis H Giesing,
  Chief Development Officer
• Jean Jacques Bienaime,
  
• Max Rosett,
  EVP, Operations & CFO
• James P Boylan,
  
• Philip Tsai,
  Chief Technology Officer
• Franklyn G Prendergast,
  Director
• Sandra M Swain,
  
• I Wistar Iii Morris,
  10% owner
• Richard F Fitzgerald,
  Chief Financial Officer
• John L Lamattina,
  Director
• Michael Rapp,
  Director
• Corleen M. Roche,
  Chief Financial Officer
• Philip Wagenheim,
  
• Richard A Baron,
  Director
• Matthew K Robinson,
  Chief Technology Officer
• Purnanand D Sarma,
  President and CEO
• Clay B Siegall,
  President and CEO
• Isaac Barchas,
  
• Phil Noland Roberts,
  Chief Technology Officer
• Carol Schafer,
  
• Kinney Horn,
  CHIEF BUSINESS OFFICER
• Jack Higgins,
  Chief Scientific Officer
• Robert Lechleider,
  Chief Medical Officer
• Bruce Turner,
  Chief Strategy Officer